Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab (AK112) in advanced solid tumors
NCT04597541Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in solid tumor, sponsored by Akeso, Inc.. Started Oct 2020; status: completed.
02
Drugs
ivonescimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04597541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04597541.